Nuveen’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $407K | Buy |
339,073
+2,201
| +0.7% | +$2.68K | ﹤0.01% | 2915 |
|
|
2025
Q4 | $331K | Hold |
336,872
| – | – | ﹤0.01% | 3017 |
|
|
2025
Q3 | $424K | Hold |
336,872
| – | – | ﹤0.01% | 2955 |
|
|
2025
Q2 | $377K | Sell |
336,872
-42,216
| -11% | -$49.1K | ﹤0.01% | 2966 |
|
|
2025
Q1 | $300K | Buy |
379,088
+61,817
| +19% | +$75.8K | ﹤0.01% | 3045 |
|
|
2024
Q4 | $523K | Hold |
317,271
| – | – | ﹤0.01% | 2971 |
|
|
2024
Q3 | $1.11M | Sell |
317,271
-6,733
| -2% | -$26.2K | ﹤0.01% | 2715 |
|
|
2024
Q2 | $1.06M | Buy |
324,004
+24,348
| +8% | +$107K | ﹤0.01% | 2701 |
|
|
2024
Q1 | $2.2M | Sell |
299,656
-14,915
| -5% | -$92.3K | ﹤0.01% | 2360 |
|
|
2023
Q4 | $1.18M | Buy |
314,571
+27,621
| +10% | +$65.2K | ﹤0.01% | 2666 |
|
|
2023
Q3 | $608K | Sell |
286,950
-1,771
| -0.6% | -$5.87K | ﹤0.01% | 2777 |
|
|
2023
Q2 | $1.37M | Buy |
288,721
+68,144
| +31% | +$376K | ﹤0.01% | 2514 |
|
|
2023
Q1 | $1.26M | Sell |
220,577
-76,906
| -26% | -$464K | ﹤0.01% | 2518 |
|
|
2022
Q4 | $3M | Buy |
297,483
+37,533
| +14% | +$705K | ﹤0.01% | 2196 |
|
|
2022
Q3 | $5.83M | Sell |
259,950
-172,300
| -40% | -$4.98M | ﹤0.01% | 1813 |
|
|
2022
Q2 | $10.7M | Sell |
432,250
-62,794
| -13% | -$1.73M | ﹤0.01% | 1460 |
|
|
2022
Q1 | $18.7M | Buy |
495,044
+36,996
| +8% | +$1.43M | 0.01% | 1230 |
|
|
2021
Q4 | $26.8M | Sell |
458,048
-18,183
| -4% | -$1.03M | 0.01% | 1050 |
|
|
2021
Q3 | $28.2M | Buy |
476,231
+7,367
| +2% | +$578K | 0.01% | 1030 |
|
|
2021
Q2 | $40.7M | Buy |
468,864
+9,839
| +2% | +$793K | 0.01% | 861 |
|
|
2021
Q1 | $37.8M | Sell |
459,025
-5,729
| -1% | -$549K | 0.01% | 884 |
|
|
2020
Q4 | $42.3M | Sell |
464,754
-34,769
| -7% | -$2.16M | 0.01% | 783 |
|
|
2020
Q3 | $20M | Sell |
499,523
-31,457
| -6% | -$1.1M | 0.01% | 1066 |
|
|
2020
Q2 | $18.2M | Buy |
530,980
+142,207
| +37% | +$4.24M | 0.01% | 1109 |
|
|
2020
Q1 | $8.63M | Buy |
388,773
+46,368
| +14% | +$1.17M | ﹤0.01% | 1387 |
|
|
2019
Q4 | $6.7M | Buy |
342,405
+28,253
| +9% | +$449K | ﹤0.01% | 1834 |
|
|
2019
Q3 | $4.88M | Buy |
314,152
+14,739
| +5% | +$283K | ﹤0.01% | 1966 |
|
|
2019
Q2 | $6.08M | Buy |
299,413
+239,253
| +398% | +$4.31M | ﹤0.01% | 1875 |
|
|
2019
Q1 | $1.06M | Sell |
60,160
-17,839
| -23% | -$282K | 0.01% | 732 |
|
|
2018
Q4 | $1M | Sell |
77,999
-15,888
| -17% | -$222K | 0.01% | 716 |
|
|
2018
Q3 | $1.53M | Buy |
93,887
+10,619
| +13% | +$126K | 0.01% | 689 |
|
|
2018
Q2 | $944K | Buy |
83,268
+29,205
| +54% | +$322K | 0.01% | 747 |
|
|
2018
Q1 | $528K | Buy |
+54,063
| New | +$518K | ﹤0.01% | 881 |
|
Other funds holding FATE
RG
VCM
VPM
JJ
Nuveen's FATE Position: Q1 2026 in Review
Nuveen increased its Fate Therapeutics (FATE) stake by 0.65% in Q1 2026, buying an estimated $2.68K and bringing the position to 339,073 shares worth $407K. The position accounts for ﹤0.01% of the portfolio, ranked #2915.
Nuveen first reported a position in FATE in Q1 2018 and has held it in 33 quarters since. The position peaked at $42.3M in Q4 2020. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.
- Nuveen held 339,073 shares of Fate Therapeutics worth $407K as of Q1 2026.
- Nuveen bought 2,201 Fate Therapeutics shares in Q1 2026, an estimated $2.68K.
- Fate Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2915 holding.
- Nuveen first reported a position in Fate Therapeutics in Q1 2018 and has held it in 33 quarters since.
- Nuveen's Fate Therapeutics position peaked at $42.3M in Q4 2020.
- 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.
Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.